Silicon Valley Bank (SVB) is the 16th US bank. SVB has lend 50% of startup money for technology and life science companies. Client funds total $342 billion and $74 billion in total loans. SVB failure has impacted the biotech industry… Read More »Silicon Valley Bank (SVB)
In our last blog on preclinical drug evaluation (Preclinical safety pharmacology in a new era; Drug Discovery Today Volume 27, # 1 Jan. 2022) we discuss how conventional safety testing has not been able to identify safety issues prior the… Read More »Can preclinical drug development predict adverse events (AE) in clinical trials?
In this blog on preclinical drug evaluation redefinitions (Preclinical safety pharmacology in a new era; Drug Discovery Today Volume 27, # 1 Jan. 2022) we discuss the core battery (CB) tests that pharmaceutical companies used the last 20 years to… Read More »Preclinical core battery safety testing: how useful is it?
An accurate collection of journal articles from 2020 and 2021 on preclinical safety pharmacology gathered relevant peer reviewed papers focused on the challenges that are redefining preclinical and toxicology milestones in drug evaluation (Preclinical safety pharmacology in a new era;… Read More »Transforming preclinical assessment to meet clinical relevance
Safety surveillance is an objective in the pharmaceutical and devices industry that becomes a challenge once the drug/device is approved for commercialization. The US Regulatory Agency, Food and Drug Administration (FDA) has suggested to explore the use of real-world data… Read More »Exploration of Real-World Data for Drug Safety Monitoring
Randomized clinical trials (RCT) have been the reference of excellence in evidence-based medicine to collect information about the safety profile and efficacy of a drug that has not yet been released on the market. These RCTs are carried out in… Read More »Randomized clinical trials versus real-world evidence